A device for supporting the breast milk microbiome.

微生物群描述了生活在我们身上和体内的微生物的集合，包括细菌。一个健康的微生物群在调节消化、免疫和代谢功能方面至关重要。无法**获得母乳的婴儿**贡献了婴儿肠道中40%**的第一种有益细菌，他们**容易**感染与微生物有关的疾病，如坏死性小肠结肠炎(NEC)、糖尿病、IBS和肥胖。然而，目前全球**母乳喂养率**很低，某些婴儿，如早产、剖腹产和配方奶粉喂养的婴儿，获得母乳的机会减少。因此，这些婴儿特别容易感染上述疾病。BoobyBiome热衷于**赋予父母**权力**，并通过利用微生物群的力量，为那些**无法**或难以母乳喂养的人设计产品，改善他们婴儿的**健康**。目前，BoobyBiome正在开发一种**母乳衍生的**微生物群补充剂，用于**微生物群受损**的婴儿。在进行BoobyBiome的研究和开发时，我们已经意识到，一些母乳喂养方法**会削弱母乳中阳性微生物群落的生存能力**。考虑到这一点，我们努力实施一种**多方面的**方法来改善婴儿的肠道健康，通过**恢复这些婴儿缺乏的细菌。通过这个项目，BoobyBiome打算开发一种**优化**母乳的方法，以便所有婴儿都能够获得与健康微生物群相关的大量功能，无论他们是如何获得母乳的。在这个项目中，BoobyBiome将1)开发**原型**，2)进行原型**测试**的有效迭代，3)以**专利、商标和最终产品完成。**作为BoobyBiome的首席执行官，**博士*Lydia Mapstone**，我有信心作为**女性企业家**和科学家的**团队，实现这些交付成果，同时我们努力成为婴儿微生物组领域的**领导者**。完成这些里程碑的关键是我们的**经验丰富的顾问团队**以及与学术界的密切联系，包括我们**伦敦大学学院儿童健康研究所的科学合作者**Bajaj-Elliott博士**。*有效**和**负担得起**母乳微生物群落使所有婴儿都能发展出健康的微生物群，每个父母都能提供这种微生物群。最终，BoobyBiome的目标是提供该项目的产品，让所有婴儿都能接触到，包括剖腹产、配方奶婴儿、早产儿和同性父母的婴儿。我们致力于生产一种**科学有效**的产品，它有可能在医疗保健领域产生真正的**改变**。通过这样做，我们将成为所有家长信赖和信赖的公司。

The **microbiome** describes the collection of microorganisms, including bacteria, which reside on and in us. A healthy microbiome is crucial in regulating digestive, immune and metabolic functions. Babies **without** access to breastmilk, which **contributes 40%** of the first beneficial bacteria in infants' guts, are **vulnerable** to microbiome-related diseases such as necrotising enterocolitis (NEC), diabetes, IBS and obesity. However, current global rates of **breastfeeding are poor**, with certain babies such as preterm, C-section and formula-fed infants having reduced access to breastmilk. Consequently, these babies are particularly vulnerable to the aforementioned diseases.BoobyBiome is passionate about **empowering parents** and improving the **health** of their babies through designing products for those **unable** or struggling to breastfeed, by harnessing the power of the microbiome. Currently, BoobyBiome is developing a **breastmilk-derived** microbiome supplement for infants with **compromised microbiomes**. In conducting research and development for BoobyBiome, we have realised that some methods of breastfeeding **diminish the viability** of positive microbial communities in breast milk. With this in mind, we endeavour to implement a **multi-faceted** approach to improving infant gut health by **recovering** the bacteria that these babies are lacking.With this project, BoobyBiome intends to develop a method for **optimising** breastmilk such that all babies may be able to receive the vast array of functions associated with a healthy microbiome, irrespective of how they receive their milk. In this project BoobyBiome will 1) develop a **prototype**, 2) conduct effective iterations of prototype **testing** and 3) finish with a **patented, trademarked and finalised product.**As CEO of BoobyBiome, **Dr.** **Lydia Mapstone**, I am confident in our ability as a **team of female entrepreneurs** and scientists to meet these deliverables, in tandem with our efforts to be **leaders** in the infant microbiome sector. Key to completion of these milestones is our **experienced advisory team** and close associations with the academic community, including our scientific collaborator **Dr. Bajaj-Elliott** of the **UCL Institute of Child Health.****Effective** and **affordable** access to breastmilk microbial communities allows for all babies to develop a healthy microbiome and every parent to provide that. Ultimately, BoobyBiome aims to deliver a product from this project that is accessible to all babies, including C-section, formula-fed babies, preterm babies and babies of same-sex parents. We are committed to producing a **scientifically-valid product** which has the potential to exert real **change** in the healthcare sector. In doing so, we will be a reliable and trusted company to all parents.